Premium
Formulation and characterization of poly ( d , l ‐lactide‐ co ‐glycolide) nanoparticle containing vascular endothelial growth factor for gene delivery
Author(s) -
Yi F.,
Wu H.,
Jia G.L.
Publication year - 2006
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.2006.00702.x
Subject(s) - transfection , plga , gene delivery , vascular endothelial growth factor , in vivo , genetic enhancement , angiogenesis , in vitro , nanoparticle , chemistry , biophysics , microbiology and biotechnology , materials science , nanotechnology , biology , gene , cancer research , biochemistry , vegf receptors
Summary Objective: The stability, in vitro release, in vitro cell transfection efficiency and in vivo gene transfer of vascular endothelial growth factor (VEGF 165 ) plasmid DNA‐loaded poly( d , l ‐ lactide ‐ co ‐glycolide) (PLGA) nanoparticles were investigated. Methods: DNA‐loaded nanoparticles were prepared with PLGA bearing VEGF 165 plasmid DNA and characterized with respect to morphology, size and encapsulation efficiency. The gene transfer efficiency of nanoparticles was tested in vitro on the cultured myocardial cells. And then the suspension of VEGF‐loaded nanoparticles (VEGF‐NPs) was injected into myocardial tissues in vivo to observe the process of nanoparticles as vectors for gene transfer to cardiac myocytes and to detect its biological effect and evaluate angiogenesis. Results: The encapsulation efficiency of the VEGF‐NPs was 58·06 ± 2·8% and their diameter ranged 100–300 nm. VEGF gene could be successfully transfected into myocardial cells by nanoparticles, which significantly enhanced gene transfection efficiency. A great number of nanoparticles were seen in the myocardial cytoplasm and nucleus. Furthermore, the nanoparticles began to dissolve and degrade. There was a significant increase in the number of capillaries in the VEGF‐NPs group when compared with the plasmid DNA group. Conclusion: The PLGA nanoparticles are capable of DNA delivery to cardiac myocytes for treating ischaemic myocardium. The direct gene transfer of VEGF‐NPs into ischaemic rabbit myocardium can improve cardiac function and increase the number of capillaries.